Decitabine (DAC) is one of the demethylation agents which has been reported to induce and improve several TAAs, such as MAGE-A1, MAGE-A2, MAGE-A3 and MAGE-A6 (54–56), and especially induce and/or upregulate the expression of NY-ESO-1 in melanoma (30) and renal cancer cells but not in normal epithelial cells (57). This evidence concerns the gene MAGEA3 and renal carcinoma.